The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
Cardiovascular disease (CVD) is the leading cause of mortality worldwide, and its prevalence is increasing worldwide. Statins are the mainstay of treatment but do not address all aspects of CVD risk. Other lipid-lowering therapies are available but are less effective than statins. New therapies to lower low-density-lipoprotein cholesterol (LDL-C) by as much as statins, to reduce triglycerides (TGs), and to modify the metabolism of high-density lipoproteins (HDLs) are in development.
Department of Cardiology, St Thomas' Hospital, King's College Academic Health Partners, British Heart Foundation Centre of Cardiovascular Excellence, London, UK.
R
R
Hajhosseiny
Department of Cardiology, St Thomas' Hospital, King's College Academic Health Partners, British Heart Foundation Centre of Cardiovascular Excellence, London, UK.
I
I
Sabir
Department of Cardiology, St Thomas' Hospital, King's College Academic Health Partners, British Heart Foundation Centre of Cardiovascular Excellence, London, UK.
K
K
Khavandi
Department of Metabolic Medicine and Chemical Pathology, Guy's & St Thomas' Hospitals, London, UK.
A S
AS
Wierzbicki
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001647:Bile Acids and Salts / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D008078:Cholesterol, LDL / Q000378:metabolism; D058607:Fibric Acids / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors / Q000235:genetics; D012697:Serine Endopeptidases / Q000235:genetics; D014280:Triglycerides / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D016376:Oligonucleotides, Antisense; D047492:Peroxisome Proliferator-Activated Receptors; D014280:Triglycerides; C106092:microsomal triglyceride transfer protein; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases